Cochrane · systematic review · CD004447
Recombinant growth hormone therapy for X‐linked hypophosphatemia in children
Smith, S, Remmington, T · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 33.3%Low 3 · 50%Moderate 1 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings ‐ recombinant growth hormone compared with placebo or no intervention for children with X‐linked hypophosphataemia
Population: children with X‐linked hypophosphataemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Longitudinal growth: change in height SDS Summary of findings ‐ recombinant growth hormone vs placebo or no intervention | MD 0 | 2 studies · 20 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Measures of mineral metabolism: change in serum phosphate mmol/L Summary of findings ‐ recombinant growth hormone vs placebo or no intervention | MD 0.18 [0.08, 0.28] | 2 studies · 20 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Measures of endocrine function function: change in levels of alkaline phosphatase IU/L Summary of findings ‐ recombinant growth hormone vs placebo or no intervention | no estimate extracted | 2 studies · 20 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Measures of renal function: change in TmP/GFR Summary of findings ‐ recombinant growth hormone vs placebo or no intervention | MD 0.01 | 2 studies · 20 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Body proportions: sitting height SDS Summary of findings ‐ recombinant growth hormone vs placebo or no intervention | no estimate extracted | 1 study · 15 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects Summary of findings ‐ recombinant growth hormone vs placebo or no intervention | no estimate extracted | 2 studies · 20 participants | Low Downgraded: risk of bias, imprecision, inconsistency |